参松养心胶囊联合美托洛尔治疗室性早搏的Meta分析  

A Meta analysis of Shensongyangxin capsule combined metoprolol in treatment of ventricular premature beats

作　　者：刘万里[1] 黄鹤[1] 李君[1] 梅阳[1] 

机构地区：[1]武汉大学人民医院心内科,湖北武汉430060

出　　处：《心血管康复医学杂志》2015年第1期79-84,共6页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：国家973计划资助项目(2012CB518604)

摘　　要：目的:比较参松养心胶囊联合美托洛尔与单用美托洛尔治疗室性早搏的疗效。方法:计算机检索Cochrane图书馆、MEDLINE、EMbase、万方、CNKI、CBM,手工检索参松养心胶囊联合美托洛尔治疗室性早搏2005年8月-2013年8月发表的相关文献,应用Rev Man5.0软件对数据进行Meta分析。结果:治疗组患者症状缓解情况显著优于对照组[(Z=8.28,P<0.00001;比值比(OR)=6.17,95%CI(4.01,9.48)];动态心电图改善治疗组均显著优于对照组[(Z=9.37,P<0.00001),OR=3.41,95%CI(2.64,4.40)];药物不良反应两组相比差异无统计学意义[Z=1.47,P=0.14;OR=0.70,95%CI(0.43,1.13)]。各漏斗图基本对称,存在偏倚可能性小。结论:参松养心胶囊联合美托洛尔治疗室性早搏较单用美托洛尔效果好,且不增加药物不良反应。Objective：To compare the therapeutic effects between Shensongyangxin capsule combined metoprolol and metoprolol monotherapy in treating ventricular premature beats.Methods：The related literature of Shensongyangxin capsule combined metoprolol in treatment of ventricular premature beats published from Aug 2005 to Aug 2013 were searched by computer from Cochrane Library,MEDLINE,EMbase,Wangfang Data,China National Knowledge Infrastructure （CNKI）and Chinese biomedical literature database （CBM）,and were searched manually.RevMan 5.0 software was used to perform Meta analysis on data.Results：Symptomatic relief in treatment group was signifi-cantly better than that of control group [（Z=8.28,P 〈0.00001;OR=6.17,95%CI （4.01,9.48）];dynamic ECG improvement in treatment group was significantly better than that of control group [Z=9.37,P 〈0.00001;OR=3.41,95%CI （2.64,4.40）];there was no significant difference in incidence rate of adverse drug reaction be-tween two groups [Z=1.47,P =0.14;OR=0.70,95%CI （0.43,1.13）].All funnel schemas were symmetry in general,so there was small possibility of bias.Conclusion：Shensongyangxin capsule combined metoprolol possesses better therapeutic effect than metoprolol monotherapy in treating ventricular premature beats,and it doesn′t in-crease adverse drug reactions.

关 键 词：室性早搏复合征 美托洛尔 META 分析 

分 类 号：R541.7[医药卫生—心血管疾病]